Some patients with irritable bowel syndrome are begging the FDA to allow Lotronex (alosetron) back on the market

March 2002

Some patients with irritable bowel syndrome are begging the FDA to allow Lotronex (alosetron) back on the market.

And the FDA is listening.

Many patients benefited from Lotronex to control debilitating cramping and diarrhea. The problem is that sometimes it was TOO effective...causing severe constipation and ischemic colitis.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote